Search Results
Sep 09, 2026, 07:30 ET Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation
RAMAT-GAN, Israel, Sept. 9, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic and oncology diseases, today announced a corporate
More news about: Galmed Pharmaceuticals Ltd.
Aug 19, 2026, 07:00 ET Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology
Aug. 19, 2026 /PRNewswire/ -- Colospan Ltd., a wholly owned subsidiary of Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD), today announced the successful completion of a feasibility study supporting the development of a novel intraoperative colon tissue quality assessment
More news about: Galmed Pharmaceuticals Ltd.
Aug 17, 2026, 09:15 ET Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models
RAMAT-GAN, Israel, Aug. 17, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic and oncology diseases, today announced significant
More news about: Galmed Pharmaceuticals Ltd.
Jul 28, 2026, 07:00 ET Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market
RAMAT-GAN, Israel, July 28, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic and oncology diseases, today announced continued
More news about: Galmed Pharmaceuticals Ltd.
Jul 16, 2026, 07:30 ET Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol
RAMAT-GAN, Israel, July 16, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic and GI oncology diseases, today announced
More news about: Galmed Pharmaceuticals Ltd.
Jun 22, 2026, 07:00 ET Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition
Colospan Ltd. ("Colospan") provides Galmed Pharmaceuticals Ltd. ("Galmed") (NASDAQ: GLMD) with a commercially ready product in the EU/Israel (CE marked under MDR) with a dedicated OPS code to accelerate reimbursement in GermanyStrategic and Financial HighlightsRestructured
More news about: Galmed Pharmaceuticals Ltd.
Jun 08, 2026, 08:10 ET Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market
RAMAT GAN, Israel, June 8, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. ("Galmed") (NASDAQ: GLMD) today announced that it has entered into a definitive agreement to acquire Colospan Ltd. ("Colospan"), a commercial-stage medical device company that
More news about: Galmed Pharmaceuticals Ltd.
Jun 02, 2026, 07:30 ET Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis
RAMAT-GAN, Israel, June 2, 2026 /PRNewswire/ -- Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and GI oncology diseases, today announced
More news about: Galmed Pharmaceuticals Ltd.
May 14, 2026, 07:30 ET Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg
RAMAT-GAN, Israel, May 14, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, announced today major milestone
More news about: Galmed Pharmaceuticals Ltd.
May 06, 2026, 07:30 ET Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics
Israel, May 6, 2026 /PRNewswire/ -- Tissue Dynamics Ltd. and Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, today announced a collaboration
More news about: Galmed Pharmaceuticals Ltd.
Apr 14, 2026, 07:30 ET Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers
RAMAT-GAN, Israel, April 14, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver disease and GI oncological therapeutics, announced today a research
More news about: Galmed Pharmaceuticals Ltd.
Apr 09, 2026, 07:30 ET Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol
RAMAT-GAN, Israel, April 9, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced
More news about: Galmed Pharmaceuticals Ltd.
Mar 31, 2026, 16:15 ET Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025
TEL AVIV, Israel, March 31, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced
More news about: Galmed Pharmaceuticals Ltd.
Jan 30, 2026, 16:15 ET Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification
TEL AVIV, Israel, Jan. 30, 2026 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, today announced
More news about: Galmed Pharmaceuticals Ltd.
Dec 08, 2025, 08:30 ET Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting
RAMAT-GAN, Israel, Dec. 8, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced
More news about: Galmed Pharmaceuticals Ltd.
Dec 04, 2025, 08:30 ET Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH
RAMAT-GAN, Israel, Dec. 4, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced
More news about: Galmed Pharmaceuticals Ltd.
Dec 01, 2025, 08:30 ET Galmed Issues CEO Letter to Shareholders
TEL AVIV, Israel, Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today
More news about: Galmed Pharmaceuticals Ltd.
Nov 26, 2025, 08:30 ET Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
TEL AVIV, Israel, Nov. 26, 2025 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications,
More news about: Galmed Pharmaceuticals Ltd.
Nov 18, 2025, 08:30 ET Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine
RAMAT-GAN, Israel, Nov. 18, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications,
More news about: Galmed Pharmaceuticals Ltd.
Nov 17, 2025, 08:30 ET Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga® and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro
RAMAT-GAN, Israel, Nov. 17, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, cardiometabolic diseases and GI oncological therapeutics, announced
More news about: Galmed Pharmaceuticals Ltd.